Colorectal cancer (CRC) is a leading cause of death from cancer worldwide. Thus, there is an emerging need for new experimental models that allow identification and validation of biomarkers for CRC-specific progression. In this study, we propose a repeated sphere-forming assay as a strategy to select a malignant subpopulation from a CRC line, HCT116. We validated our assay by confirming that three canonical stemness markers, Nanog, Oct4, and Lgr5, were up-regulated in the sphere state at every generation of the selection assay. The resulting line, after eight rounds of selection, exhibited an increased sphere-forming capacity in vitro and tumorgenicity in vivo. Furthermore, dipeptidase 1 (DPEP1) was identified as the major differentially expressed gene in the selected clone, and depletion of DPEP1 suppressed the elevated sphere-forming capacity in vitro and tumorgenicity in vivo. Overall, we have established an experimental strategy for the isolation of a malignant subpopulation from a CRC cell line. Results from our model also suggested that DPEP1 can serve as a promising prognostic biomarker for CRC.
Introduction
Colorectal cancer (CRC) is the fourth most common cause of cancer death worldwide and is also a common neoplastic disease in modern countries 1, 2 . As with many other types of cancers, the development of CRC from benign adenomas to malignant carcinomas is thought to result from long-term accumulation of mutations during the course of disease progression 3 . Because the survival of CRC patients is closely linked to the time of diagnosis and stage of the tumor 4 , it is increasingly important to identify specific factors involved in CRC progression to serve as prognostic markers. A good experimental model that spans a wide range of malignancies would facilitate identification and validation of such CRC markers.
It has been proposed that cancer stem cells (CSCs), a subpopulation of cancer cells that has self-renewing features to promote tumor growth and resistance to chemotherapy, are the most malignant subset of cells responsible for the recurrence and metastasis of CRC 5, 6 . The sphereforming assay is the gold-standard for isolating CSC-like cells. The history of the assay can be traced back to the late 1960s when it was used to study neurogenesis in neural stem cells 7 .
Specifically, the sphere-forming assay was used to identify cells with higher neurogenic potentials both in clonality and multipotent differentiation 8 . Since then, this assay has been employed to investigate stem cells in a variety of normal tissues 8 . Scientists have adopted the sphere-forming assay to form tumorspheres in many kinds of cancers, including brain 9 , breast 10 , and colorectal 11, 12 . These tumorspheres reportedly have similar self-renewal characteristics and express the same canonical stemness markers (such as Nanog 13 ) as normal stem cells. A caveat, however, exists for using tumorspheres, or CSC-like cells, as platforms to study CRC progression. Because tumorspheres are present acutely in a different physiological state (apart from the long-term adherent culture), the measured phenotypes may only reflect transient 14 ,
and not, stable properties of the cells.
Inspired by such limitations, we used a repeated sphere-forming assay as a strategy to select a malignant cell line that was phenotypically stable. This is conceptually parallel to our previous establishment of a series of metastatic cell lines using repeated invasion assays 15, 16 . Such model cell lines have been used to identify genes or cellular phenotypes that are associated with metastasis 16, 17 . In this study, with a repeated sphere-forming assay, we aimed to select a malignant clone from a HCT116 CRC cell line. Using RNA-seq to compare the transcriptome between the selected clone and its parental cell line, we also identified the gene responsible for malignancy both in vitro and in vivo.
Results

Evolution and selection of a cancer cell line using repeated sphere-forming assays
Our experimental design is illustrated in Figure 1 . With an ultra-low attachment dish, we generated tumorspheres using the sphere-forming assay. While the majority of cells died during culturing, a small population (i.e., CSC-like cells) was able to form spheres. These spherederived CSC-like cells (SDCSCs) were isolated, and a portion was collected and subjected to experimental validations. The remaining cells were dissociated and re-plated onto a regular dish as adherent cells (sphere-derived adherent cells, or SDACs). SDACs were allowed to expand, some were frozen in stock vials, and after a recovery of 14 days, cells were again cultured in an ultra-low attachment dish to form spheres for the next round of selection ( Figure   1 ). For simplicity, we abbreviated 'generation' as 'G', 'SDCSCs' as 'S', and 'SDACs' as 'D'.
For example, first-generation SDCSCs are designated as 'G1S', and first-generation SDACs are designated as 'G1D'.
HCT116 cells, a human CRC cell line, were used as our model cell line. At the beginning of our assay, HCT116 cells were subjected to a one-time homogenizing sphere-forming assay and re-plated as adherent cells. Such homogenized HCT116 cells were considered parental and designated as 'G0'. Beginning with this parental line, we performed repeated sphere-forming assay and recovery procedures for the generation of SDCSCs and SDACs. Eighth-generation SDCSCs and SDACs are designated G8S and G8D, respectively.
Canonical stemness markers are transiently expressed in SDCSCs
To validate that the SDCSCs generated from our sphere-forming assay were CSC-like tumorspheres, we tested the expression of several canonical stemness markers, including the pluripotent markers Nanog and Oct4 18 , and a stem cell marker of the intestinal epithelium, Lgr5 19 . SDACs and SDCSCs from G0 (parental) to G8 were collected. The quantitative real-time polymerase chain reaction (qRT-PCR) revealed that the mRNA expression of these three markers was significantly higher in SDCSCs at every generation than at G0 (Figure 2A ).
Similar results were observed by immunofluorescent staining of the marker proteins at G1 and G8 ( Figure 2B ). Up-regulation of canonical markers in SDCSCs validated our repeated sphereforming assay. The expression of these three markers, however, appeared to be only transient, as their levels were close to that of G0 in SDACs at every generation (Figure 2A and B).
Because the expression patterns of Nanog were the most robust among the three markers, we chose to focus on it for investigating the observed transient expression behavior. To analyze the stability of Nanog expression, we performed a time-course experiment. G1S formed spheres, which were collected and re-plated onto a regular dish as adherent cells to be harvested at days 1, 3, 7, and 14. The expression of Nanog was high in SDCSCs and remained high at day 1 in SDACs, but gradually decayed from days 3 to 14 in SDACs, at both the mRNA and protein levels ( Figure 2C and D). Such a transient pattern suggests that up-regulation of these markers may stem from the sphere state (i.e., a consequence of the sphere-forming assay) and was not a stable phenotype of the cells.
Sphere-forming capacity increases significantly after eight rounds of selection
To test whether eight rounds of selection resulted in a cell line that was phenotypically more malignant, we compared the sphere-forming capacities of parental and eighth generation cells in vitro 8 . While the morphology of SDACs was similar between G1D and G8D, the size of the spheres was significantly greater in G8S than in G1S ( Figure 3A and B, right). The number of spheres that formed was also higher at G8 ( Figure 3B , left).
RNA sequencing identifies DPEP1 as a highly expressed gene in the selected clone
The greater sphere-forming capacity at G8 suggests that our repeated sphere-forming assay was able to select for a more malignant subpopulation ( Figure 3A and B). Therefore, we searched for stably up-regulated genes in the selected clone that might be responsible for the malignancy. RNA sequencing was performed to identify genes differentially expressed in G8D
as compared to G0 ( Figure 4A ), and DPEP1was showed to be up-regulated to the greatest extent among the protein-coding genes when the differential expression in the sphere state was included as a reference control ( Figure 4B ). The up-regulation of DPEP1 mRNA in G8D was confirmed by qRT-PCR ( Figure 4C ). Because DPEP1 expression is higher in paired tumors than in adjacent tissues 20 and in tumor tissues than in normal mucosa 21, 22 , we further studied the role of this gene in sphere formation. Two different lentiviral small hairpin RNAs were used to stably knockdown DPEP1 in G8D. Knockdown efficiency was confirmed at both the mRNA and protein levels ( Figure 4D and E). Inhibition of DPEP1 led to a marked decrease of the sphere-forming capacity in G8D ( Figure 4F and G), suggesting that over-expression of DPEP1 promotes malignancy.
The selected clone exhibits higher DPEP1-dependent tumorgenicity in vivo
To investigate whether the selected clone possessed higher DPEP1-dependent tumorgenicity in vivo, tumor growth was examined in a xenograft model with severely immunodeficient NSG (NOD/SCID/gamma; i.e., lacking T/B/NK cells) mice 23 . As shown in Figure 5A , tumor size was significantly larger with G8D than with G0 clones, indicating a stronger tumorgenicity after eight rounds of selection. The ablation of DPEP1 greatly reduced tumorgenicity in G8D
to that of G0 ( Figure 5A ; quantification of tumor weights and volumes is shown in Figure 5B and C). Taken together, these data confirm that our repeated sphere-forming strategy can successfully select a highly tumorigenic clone. DPEP1 was stably over-expressed in G8D and responsible for the elevated tumorgenicity.
Discussion
Stem cells are defined by their ability to self-renew and differentiate into a variety of cell types.
The concept has expanded from embryonic stem cells, to adult stem cells, to CSCs. The sphereforming assay is used traditionally to identify cells that possess stem cell characteristics, and it has also been adopted to characterize CSCs. Previously, when cancer cells were passaged serially as tumorspheres (i.e., CSC-like cells), later generations were more tumorigenic than parental cells 24 . However, because cells in tumorspheres are cultured temporarily in a condition that is apart from their usual condition, it is likely that the phenotypes measured merely reflect an acute state temporarily. In other words, the expression of markers and phenotypes may be only transient 14 . Indeed, with the three canonical stem cell markers Nanog, Oct4, and Lgr5, we
showed that, while they were up-regulated in tumorspheres (SDCSCs), the level decreased to close to the parental level when the spheres were re-plated as adherent cells (SDACs) ( Figure   2 ). Based on this finding, we adopted an alternative "intermittent" strategy. Specifically, after 14 days of sphere formation, cells were allowed to rest in the adherent state for 14 days before the next sphere-forming assay ( Figure 1 ). With this experimental strategy, we generated cell lines and identified stable phenotypes. Another benefit of the strategy was that cells could be expanded and stored in the resting SDAC state, and could be recovered at every generations.
As opposed to continuous propagation as tumorspheres 24 , which only lasts for a limited duration in our hands (data not shown), in theory, with the intermittent strategy, the assay can be carried out for infinite generations.
With this intermittent strategy, we were able to isolate a clone after eight rounds of sphere formation that, in its adherent state, was more tumorigenic than the parental line ( Figure 5 ).
Because the number of selection rounds was relatively small, it is probable that the selected clone (G8D) was a preexisting subpopulation within the heterogeneous parental line. However,
given the genomic instability of cancer cells, it is likely that increasing the number of selections would allow accumulation of new mutations during the course of the experiment. Thus, the system has the potential to be used to carry out "experimental cancer evolution" 25 . In such a case, the hypoxic microenvironment within the tumorsphere can serve as the selection pressure that drives evolution towards a potentially more devastating phenotype 26 . Given the previous success in experimental evolution of multicellularity (i.e., stemness) from unicellular
Saccharomyces cerevisiae 27 and Chlamydomonas 28 , it seems reasonable that we may be able to experimentally evolve stable stemness in cancer. Such a stable CSC-like line would be a good experimental model for drug screening for anti-CSC agents.
In our transcriptome analysis of the selected clone, we identified DPEP1 as the main differentially expressed gene ( Figure 4A ). We also showed that DPEP1 was responsible for the elevated sphere-forming capacity in vitro ( Figure 4E and F) and tumorigenicity in vivo ( Figure   5A -C). These findings coincide with at least three previous studies that reported DPEP1 was highly expressed in malignant colorectal tissues [20] [21] [22] . Because a high DPEP1 level is associated with poor CRC patient survival 21 , our results further strengthen the concept of using DPEP1 expression as a CRC prognostic marker. Mechanistically, it has been reported that DPEP1
promotes cell proliferation in vitro 20 . Because DPEP1 is a matrix metalloproteinase, it may also promote tumor growth in vivo by degrading matrix barriers to enhance cell migration and angiogenesis 29 . Further investigations are necessary to disentangle the roles of DPEP1 that may contribute to in vivo tumor growth.
Material and Methods
Cell culture, sphere-forming assay, and preparation of SDACs supplemented with B27 (Gibco), minimum essential medium non-essential amino acids, sodium pyruvate, L-glutamine, insulin (Gibco), 20 ng/mL epidermal growth factor, 10 ng/mL basic fibroblast growth factor, and 100 U/mL penicillin/streptomycin.
To prepare SDACs, TrypLE Express (Gibco) was used to dissociate spheres, and single cells were collected by centrifugation. The cells were then resuspended in DMEM/F12 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin for 14 days before the next sphere-forming assay round.
Microscopy and immunofluorescence staining
Phase-contrast images of SDCSCs and SDACs were obtained using an inverted Axio Observer LGR5 forward: 5′-CTC CCA GGT CTG GTG TGT TG-3′; reverse: 5′-GAG GTC TAG GTA GGA GGT GAA G-3′ DPEP1 forward: 5′-CAA GTG GCC GAC CAT CTG G-3′; reverse: 5′-GGG ACC CTT GGA ACA CCA TC-3′
RNA sequencing
RNA concentrations and purity were determined by measuring the OD260/OD280 (>1.8) and OD260/OD230 (>1.6), respectively. Yield and quality were assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies). After the sample quality control procedures, mRNA from eukaryotic organisms was enriched using oligo(dT) beads. First, mRNA was fragmented randomly by adding fragmentation buffer, then cDNA was synthesized using an mRNA template and random hexamer primers, after which a custom second-strand synthesis buffer (Illumina), dNTPs, RNase H, and DNA polymerase I were added to initiate second-strand synthesis. Second, after a series of terminal repair reactions, ligation, and sequencing adaptor ligation, the double-stranded cDNA library was completed through size selection and PCR enrichment. The libraries were pooled and analyzed on an Illumina sequencer using the pairedend 150 bp RapidRun format to generate 20 million total reads per sample. Raw reads of RNAseq from the sequencing instrument first trimmed the low-quality tranche and were checked.
Spliced Transcripts Alignment to a Reference software (Illumina) was used to map spliced short-read (RNA-seq reads) to the reference genome (Ensembl GRCh38). Based on spliced alignments, transcript reconstruction and estimations of transcript abundance were conducted by Cuffquant. Gene expression was normalized by calculating the number of RNA-seq fragments per kilobase of transcript per total million fragments mapped. Cuffdiff was used to test the statistical significance of observed changes and identify genes that were differentially regulated at the transcriptional or post-transcriptional levels.
Western blot
Cells were washed with ice-cold PBS. Total cell lysates were extracted by radioimmunoprecipitation assay buffer (Millipore) supplemented with protease and phosphatase inhibitors (Roche). Protein concentrations were determined using a Bradford protein assay kit (BioRad). Exactly 30 or 100 µg of protein were separated on 10% polyacrylamide gels and then transferred onto membranes. The membranes were washed in PBS with Tween 20 (PBST). After blocking with 5% nonfat milk in PBST for 1 h at room temperature, the membranes were incubated with anti-Nanog (Santa Cruz Biotechnology, SC-293121), anti-DPEP1 (Signalway Antibody, #38797), and anti-GAPDH (GeneTex, GTX627408) antibodies overnight at 4˚C. After incubation with the corresponding secondary antibody for 1 h at room temperature, immunoreactive proteins were detected by an enhanced chemiluminescence detection system (EMD-Millipore).
Xenograft tumorigenicity assay
Xenograft tumorigenicity was determined as described previously. Briefly, HCT116 cells at different tumorsphere generations (G0 or G8D) or treatments (G8D with shVoid (non-targeting negative control shRNA) or shDPEP1 viral infection) were harvested, washed with PBS, and resuspended in DMEM/F12 medium. Cells (1 × 10 2 ) were then injected subcutaneously into the right and left flank regions of 6-week-old male NSG mice (Genomic Research Center, Taiwan). All mice were killed 28 days after injection, and tumors were surgically excised, weighed, the volume measured, and photographed. Differences in tumor progression were analyzed statistically by an analysis of variance followed by Dunnett's or Tukey's post-hoc test. P < 0.05 was considered significant. In the sphere-forming assay, the majority of cells die at the beginning of the selection process.
Spheres were dissociated to obtain single cells that were re-plated onto a regular dish to recover for 14 days. After recovery, cells were cultured in an ultra-low attachment dish to form spheres.
Orange dish: regular culture dish; green dish: ultra-low attachment dish. (n = 3 independent experiments). GAPDH was used as the reference gene. Significant differences were determined using ANOVA followed by Dunnett's test, *p < 0.05, **p < 0.01.
(D) Proteins were collected from SDCSCs at days 1, 3, 7, and 14 after re-plating as SDACs.
Expression of the Nanog protein was detected with western blot. GAPDH was used as the internal control. (bottom). SDCSCs isolated from the sphere-forming assay were allowed to recover for 14 days to obtain SDACs. Scale bar: 100 µm (SDCSCs) and 50 µm (SDACs).
(B and C) Quantification of the number and size of spheres at G1 and G8. In every condition, 1000 cells were seeded. After 14 days of sphere-formation, the number and size (diameter) of spheres were quantified with ZEN software (n > 120 cells analyzed in both G1 and G8). Data are presented as means ± S.D. Significant differences were determined using Student's t test, **p < 0.01, ****p < 0.0001. Significance differences were determined using ANOVA followed by Dunnett's test, **p < 0.01.
(F and G) Quantification of the number and size of spheres following treatment with shVoid or shDPEP1 #1/#2. In every condition, 1000 cells were seeded. After 14 days of sphereformation, the number and size (diameter) of spheres were quantified with ZEN software (n > 120 cells analyzed in both G1 and G8). Data are presented as means ± S.D. Significant differences were determined using ANOVA followed by Tukey's test, *p < 0.05, ****p < 0.0001. (B) Quantification of excised tumor weights for the indicated treatments: G0 (n = 9), G8 (n = 9), G8-short hairpin (sh)DPEP1 (n = 10), and G8-shVoid (non-targeting negative control shRNA) (n = 10). Significant differences were determined using ANOVA followed by Tukey's test, *p < 0.05, **p < 0.01, ***p < 0.001.
(C) Tumor volumes were calculated according to the formula: ((π/6) × width 2 × length) for the indicated treatments: G0 (n = 9), G8 (n = 9), G8-shDPEP1 (n = 10), and G8-shVoid (n = 10).
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